Relacorilant, a Selective Glucocorticoid Receptor Modulator, Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer: OS Analysis From a Randomized Phase II Trial

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Addition of the GR modulator relacorilant to nab-paclitaxel numerically improved OS vs nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 174 KB
Released: June 15, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seagen & Genmab

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings